Trial Profile
Phase I Study of Pre-operative Capecitabine and Lenvatinib With External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Aug 2022
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Lenvatinib (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Adverse reactions
- 05 Aug 2022 Results published in the Oncologist
- 27 Dec 2021 Status changed from active, no longer recruiting to completed.
- 24 Jun 2020 Results assessing the effectiveness and safety of lenvatinib and capecitabine combined with radiation in patients with locally advanced rectal cancer (LARC) presented at the 111th Annual Meeting of the American Association for Cancer Research - II